Filter posts

PTAB Ruling Proves Medical Innovation Under Attack

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

A diverse group of more than 100 national and state-based advocacy organizations have united to …

225th Anniversary of First U.S. Patent

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for …

CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

The Intellectual Property Track at the BIO International Convention was a chance for IP thought …

Sen Menendez Asks SEC to Investigate IPR Abuses

New Jersey Senator Bob Menendez has asked the Securities and Exchange Commissioner (SEC) to investigate …

IP Sessions at the 2015 BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues …

BIO Deputy General Counsel Testifies on Patent Reform

On Wednesday, March 18, BIO’s Deputy Counsel for Intellectual Property, Hans Sauer, testified in front …